Whether confirmed in humans, the combined use of CXCR2/PD-1 inhibitors might represent a successful strategy to improve NASH-related HCC therapy by restoring cancer immunosurveillance. Here, CXCR2 is linked to metabolic dysfunction-associated steatohepatitis.